exhibit 10. 1 execution version amended and restated exclusive license agreement this amended and restated exclusive license agreement ( “ agreement ” ) is effective as of november 24, 2008 ( the “ effective date ” ), and is restated as of this 10th day of april, 2013 ( “ restatement date ” ) by and between the university of western australia, a body corporate established pursuant to the provisions of the university of western australia act 1911, with offices at 35 stirling highway, crawley, western australia 6009 ( “ uwa ” ), on the one hand, and sarepta therapeutics, with offices at 245 first street suite 1800 cambridge, ma 02142 usa ( “ sarepta ” ) and sarepta international cv ( “ sarepta netherlands, ” and collectively with sarepta, “ licensee ” ), on the other hand. r e c i t a l s a. uwa owns and is entitled to grant license rights with respect to certain patent rights and technical information ( as defined below ) invented or developed in the course of certain research conducted under the direction of stephen d. wilson, sue fletcher, graham mcclorey, abbie adams and penny meloni ( hereinafter collectively referred to as the “ inventors ” ). b. certain of the patent rights and technical information had been previously assigned by uwa to smithkline beecham corporation doing business as glaxosmithkline ( “ gsk ” ), but have, as of the effective date, been reassigned by gsk to uwa. c. licensee is in the process of developing various products for the treatment of muscular dystrophy arising from defects in the dystrophin gene by inducing the skipping of certain exons in such gene for which the patent rights and technical information may be useful. d. uwa and licensee entered into a certain exclusive license agreement, dated as of the effective date ( the “ prior license agreement ” ), pursuant to which uwa granted to licensee certain exclusive license rights under certain patent rights and technical information relating to the treatment of duchenne muscular dystrophy by inducing the skipping of certain specified exons or blocks of exons through the use of certain specified antisense sequences ( the “ prior license rights ” ). e. licensee and uwa desire to expand the prior license rights to allow licensee to conduct research in the field of use, and to develop